

Results announcement

(for Equity Security issuer/Equity and Debt Security issuer)

Updated as at 8 May 2019



Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	12 months to March 31 2019	
Previous Reporting Period	12 months to March 31 2018	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$85,127	Up 5%
Total Revenue	\$85,127	Up 5%
Net profit/(loss) from continuing operations	\$(2,427)	Down 81%
Total net profit/(loss)	\$(2,427)	Down 81%
Interim/Final Dividend		
Amount per Quoted Equity Security	No dividends have been paid on ordinary shares and it is currently not proposed to pay dividends.	
Imputed amount per Quoted Equity Security	Not Applicable	
Record Date	Not Applicable	
Dividend Payment Date	Not Applicable	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.03	\$0.02
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's audited consolidated financial statements for the twelve months ended March 31 2019. These financial statements and the full year results commentary dated May 22 2019 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p> <p>The unlisted Redeemable preference shares issued on March 24 2017 attract a dividend rate of 9.4% per annum, or 25.8 cents per share per annum. None of the quarterly dividends (with effective dates of June 30 2018, September 30 2018, December 31 2018 and March 31 2019) were paid in cash. Accordingly, they have not been included in the table above. The dividends net of withholding taxes for these four</p>	

	quarters have been accumulated in the Redeemable Preference Share Reserve.
Authority for this announcement	
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm@aftpharm.com
Date of release through MAP	21 May 2019

Audited financial statements accompany this announcement.